| Ticker | Status | Jurisdiction | Filing Date | CP Start | CP End | CP Loss | Deadline |
|---|
| Ticker | Case Name | Status | CP Start | CP End | Deadline | Settlement Amt |
|---|
| Ticker | Name | Date | Analyst Firm | Up/Down | Target ($) | Rating Change | Rating Current |
|---|
On CNBC's “Halftime Report Final Trades,” Karen Firestone of Aureus Asset Management said Abbott Laboratories (NYSE:ABT) has a strong pipeline and the stock is starting to move.
On July 18, Abbott reported second-quarter sales of $10.38 billion, up 4%, almost in line with the consensus of $10.37 billion. Organic sales growth for the underlying base business was 9.3%, led by double-digit growth in Medical Devices. Abbott's adjusted diluted earnings per share was $1.14, beating the analyst estimates of $1.10.
Shannon Saccocia of NB Private Wealth named iShares U.S. Industrials ETF (CBOE: IYJ) as her final trade.
Don't forget to check out our premarket coverage here
Joseph M. Terranova of Virtus Investment Partners picked Nu Holdings Ltd. (NYSE:NU).
On Aug. 13, Nu Holdings reported financial results for the second quarter after the market close.
Nu Holdings reported second-quarter revenue of $2.8 billion. The Brazilian bank's top-line results were up 65% on a year-over-year basis. Nu reported second-quarter adjusted net income of $563 million, up from $263 million in the second quarter of 2023.
Nu Holdings said it added 5.2 million customers in the second quarter, bringing total customers up to 104.5 million as of June 30. Monthly average revenue per active customer came in at $11.20.
Price Action:
